Search

Home > New FDA Approvals > 083 – FDA approves abiraterone for high-risk prostate cancer; Cosentyx for scalp psoriasis; Domestic supply of isotope; 2017 record setting for generic drugs
Podcast: New FDA Approvals
Episode:

083 – FDA approves abiraterone for high-risk prostate cancer; Cosentyx for scalp psoriasis; Domestic supply of isotope; 2017 record setting for generic drugs
Category: Science & Medicine
Duration: 00:11:18
Publish Date: 2018-02-09 07:00:00
Description:

February 9, 2018

0:45 FDA approves abiraterone for high-risk prostate cancer https://www.prnewswire.com/news-releases/zytiga-abiraterone-acetate-plus-prednisone-approved-for-treatment-of-earlier-form-of-metastatic-prostate-cancer-300595759.html

1:54 Novartis receives FDA approval for Cosentyx label update to include moderate to severe scalp psoriasis https://www.prnewswire.com/news-releases/novartis-receives-fda-approval-for-cosentyx-label-update-to-include-moderate-to-severe-scalp-psoriasis-300595617.html 

3:45 FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging https://www.prnewswire.com/news-releases/fda-and-nrc-pave-way-for-the-first-domestic-supply-of-the-most-commonly-used-medical-isotope-in-diagnostic-imaging-300595907.html 

6:49 2017 was another record-setting year for generic drugs https://blogs.fda.gov/fdavoice/index.php/2018/02/2017-was-another-record-setting-year-for-generic-drugs/
Total Play: 0